BioLife Solutions (Nasdaq: BLFS) Q2 revenue climbs 21% ahead of Repligen buyout

Q: What were BioLife Solutions (BLFS) revenues in Q2 2026?

BioLife Solutions generated $28.5 million in revenue in Q2 2026, an increase of 21% from $23.4 million in Q2 2025. For the six months ended June 30, 2026, revenue was $56.0 million , up 23% from $45.5 million a year earlier.

Q: What was BioLife Solutions’ (BLFS) cash position as of June 30, 2026?

As of June 30, 2026, BioLife held $113.1 million in cash, cash equivalents and marketable securities. Working capital totaled $121.3 million , and total shareholders’ equity was $420.0 million , reflecting the impact of recent profitability and balance sheet changes.

Q: Which non-GAAP metrics does BioLife Solutions (BLFS) highlight for Q2 2026?

BioLife highlights adjusted gross margin , adjusted operating income , adjusted net income and adjusted EBITDA . For Q2 2026, adjusted gross margin was 65%, adjusted operating income $3.1 million, adjusted net income $4.2 million, and adjusted EBITDA $7.4 million, or 26% of revenue.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

BioLife Solutions reported strong second‑quarter 2026 results, with revenue of $28.5 million, up 21% from Q2 2025, and six‑month revenue of $56.0 million, up 23%. GAAP gross margin was 64% and non‑GAAP adjusted gross margin 65%. Q2 GAAP operating income reached $1.7 million, with adjusted operating income of $3.1 million.

GAAP net income from continuing operations was $45.1 million, versus a $15.3 million loss a year earlier, driven largely by a $42.4 million non‑cash income tax benefit from releasing a valuation allowance. Non‑GAAP adjusted net income was $4.2 million, and adjusted EBITDA was $7.4 million, or 26% of revenue.

As of June 30, 2026, cash, cash equivalents and marketable securities totaled $113.1 million, and shareholders’ equity was $420.0 million. BioLife also entered a definitive agreement for Repligen to acquire the company for an enterprise value of approximately $1.5 billion, paying $11.25 in cash plus 0.1442 Repligen shares per BioLife share, with closing expected in the fourth quarter of 2026 subject to BioLife stockholder, regulatory and other customary approvals.

Positive

Second‑quarter 2026 revenue grew 21% to $28.5 million, with six‑month revenue up 23% to $56.0 million versus the prior year.
Results swung to GAAP net income of $45.1 million from a loss, with non‑GAAP adjusted net income rising to $4.2 million and adjusted EBITDA reaching $7.4 million, or 26% of revenue.

Negative

None.

Filing Explained

The disclosed Repligen merger has not closed: BioLife expects completion in the fourth quarter of 2026, subject to stockholder, regulatory and other customary approvals. If completed, BioLife would cease to be publicly traded, changing the company’s status from a public listing to a privately held company.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Revenue: $28.5 million Six‑month 2026 Revenue: $56.0 million Q2 2026 GAAP Net Income: $45.1 million +4 more

7 metrics

Q2 2026 Revenue $28.5 million Three months ended June 30, 2026; up 21% from $23.4 million in Q2 2025

Six‑month 2026 Revenue $56.0 million Six months ended June 30, 2026; up 23% from $45.5 million in 2025

Q2 2026 GAAP Net Income $45.1 million Net income from continuing operations for quarter ended June 30, 2026

Non‑cash Income Tax Benefit $42.4 million Benefit recognized in Q2 2026 from release of valuation allowance

Q2 2026 Adjusted EBITDA $7.4 million Non‑GAAP adjusted EBITDA for Q2 2026, equal to 26% of revenue

Cash and Marketable Securities $113.1 million Cash, cash equivalents and marketable securities as of June 30, 2026

Repligen Transaction Enterprise Value $1.5 billion Approximate total enterprise value for proposed acquisition of BioLife by Repligen

Key Terms

non-GAAP adjusted EBITDA, valuation allowance, discontinued operations, IPR&D expense, +1 more

5 terms

non-GAAP adjusted EBITDA financial

"GAAP net income of $45.1 million ... and non-GAAP adjusted EBITDA of $7.4 million"

Non-GAAP adjusted EBITDA is a measure of a company's profitability that shows earnings before interest, taxes, depreciation, and amortization, with certain adjustments made to exclude irregular or non-recurring expenses and income. It provides a clearer picture of ongoing operational performance by filtering out items that might distort the core business results. Investors use it to better compare how well different companies are performing without the noise of one-time events.

valuation allowance financial

"Due to the release of our valuation allowance during the second quarter of 2026"

A valuation allowance is a reserve set aside to reduce the value of certain assets on a company's financial records when there is uncertainty about whether they will generate the expected benefits. It acts like a caution sign, indicating that some assets might not be fully recoverable or worth their recorded amount. This matters to investors because it provides a more realistic picture of a company's financial health and potential risks.

discontinued operations financial

"presenting its financial condition and operating results as discontinued operations for all periods"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

IPR&D expense financial

"Operating expenses include IPR&D expense of 15,521 in the second quarter of 2025"

biopreservation media medical

"Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials"

Biopreservation media are specially formulated liquids used to keep cells, tissues or biological samples alive and stable during storage and transport, like a refrigerated packing solution that prevents damage and decay. For investors, the quality of these media matters because they influence product shelf life, success of lab tests, regulatory acceptance, and logistics costs for therapies and diagnostics—factors that affect revenue, margins and market adoption.

Earnings Snapshot

Q2 2026 revenue: $28.5 million

three and six months ended June 30, 2026

Q2 2026 revenue $28.5 million increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025

Six‑month 2026 revenue $56.0 million increase of $10.5 million, or 23%, from $45.5 million for the six months ended June 30, 2025

Q2 2026 GAAP net income $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025

Q2 2026 adjusted net income $4.2 million compared with $0.6 million for the second quarter of 2025

Q2 2026 adjusted EBITDA margin 26% of revenue compared with 24% of revenue for the second quarter of 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/06/2026 - 04:09 PM Accepted by SEC EDGAR 08/06/2026 - 04:08 PM

FAQ

What were BioLife Solutions (BLFS) revenues in Q2 2026?

BioLife Solutions generated $28.5 million in revenue in Q2 2026, an increase of 21% from $23.4 million in Q2 2025. For the six months ended June 30, 2026, revenue was $56.0 million, up 23% from $45.5 million a year earlier.

How profitable was BioLife Solutions (BLFS) in Q2 2026 on a GAAP and non-GAAP basis?

In Q2 2026, BioLife reported GAAP net income from continuing operations of $45.1 million, aided by a $42.4 million non‑cash tax benefit. Non‑GAAP adjusted net income was $4.2 million, and adjusted EBITDA was $7.4 million, or 26% of revenue.

What are the key terms of Repligen’s acquisition of BioLife Solutions (BLFS)?

Repligen agreed to acquire BioLife for an enterprise value of approximately $1.5 billion. Each BioLife share will receive $11.25 in cash plus 0.1442 shares of Repligen common stock. Closing is expected in Q4 2026, subject to stockholder and regulatory approvals and customary conditions.

What was BioLife Solutions’ (BLFS) cash position as of June 30, 2026?

As of June 30, 2026, BioLife held $113.1 million in cash, cash equivalents and marketable securities. Working capital totaled $121.3 million, and total shareholders’ equity was $420.0 million, reflecting the impact of recent profitability and balance sheet changes.

Which non-GAAP metrics does BioLife Solutions (BLFS) highlight for Q2 2026?

BioLife highlights adjusted gross margin, adjusted operating income, adjusted net income and adjusted EBITDA. For Q2 2026, adjusted gross margin was 65%, adjusted operating income $3.1 million, adjusted net income $4.2 million, and adjusted EBITDA $7.4 million, or 26% of revenue.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36362

94-3076866

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400


N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common Stock, par value $0.001 per share	BLFS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, BioLife Solutions, Inc. (the “Company”) issued a press release announcing unaudited financial results and operational highlights for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						Press release, dated August 6, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	BioLife Solutions, Inc.

Date: August 6, 2026	By:	/s/ Troy Wichterman
		Name: Troy Wichterman
		Title: Chief Financial Officer

BioLife Solutions Reports Second Quarter 2026 Financial Results

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash. (August 6, 2026) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, announces financial results for the three and six months ended June 30, 2026.

“We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise,” said Roderick de Greef, Chairman and Chief Executive Officer of BioLife. “This continued performance underscores the important role our technologies play in enabling the advancement of cell and gene therapies. We look forward to building on this foundation through our announced combination with Repligen, which is expected to close in the fourth quarter of 2026.”

Second Quarter 2026 Business Highlights

•On July 21, 2026, BioLife entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5 billion, comprised of $11.25 cash and 0.1442 shares of Repligen’s common stock, on a per share basis of BioLife’s common stock. As a result of the merger, BioLife will cease to be a publicly traded company. The transaction is expected to close in the fourth quarter of 2026, subject to approval by BioLife stockholders, regulatory approvals and other customary closing conditions.

•Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.

•Our biopreservation media is embedded in 18 unique commercial CGTs as of June 30, 2026, with expectations that approvals for 8 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies.

Second Quarter 2026 Financial Results

BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance


			Page 1

Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

REVENUE

•Total revenue for the second quarter of 2026 was $28.5 million, an increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026.

•Total revenue for the six months ended June 30, 2026 was $56.0 million, an increase of $10.5 million, or 23%, from $45.5 million for the six months ended June 30, 2025.

GROSS MARGIN

•Gross margin (GAAP) for the second quarter of 2026 was 64% compared with 65% for the second quarter of 2025. Adjusted gross margin (non-GAAP) for the second quarter of 2026 was 65% compared with 66% for the second quarter of 2025.

•Gross margin (GAAP) for the six months ended June 30, 2026 was 64% compared with 66% for the six months ended June 30, 2025. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2026 was 65% compared with 67% for the six months ended June 30, 2025.

OPERATING INCOME / (LOSS)

•Operating income (GAAP) for the second quarter of 2026 was $1.7 million compared with an operating loss of $16.1 million for the second quarter of 2025. Adjusted operating income (non-GAAP) for the second quarter of 2026 was $3.1 million compared with an adjusted operating loss of $0.3 million for the second quarter of 2025.

•Operating income (GAAP) for the six months ended June 30, 2026 was $1.7 million compared with an operating loss of $16.6 million for the six months ended June 30, 2025. Adjusted operating income (non-GAAP) for the six months ended June 30, 2026 was $4.1 million compared with $0.9 million for the six months ended June 30, 2025.

NET INCOME / (LOSS)

•Net income (GAAP) for the second quarter of 2026 was $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025. Adjusted net income (non-GAAP) for the second quarter of 2026 was $4.2 million compared with $0.6 million for the second quarter of 2025. Due to the release of our valuation allowance during the second quarter of 2026, we recognized a non-cash income tax benefit of $42.4 million.


			Page 2

•Net income (GAAP) for the six months ended June 30, 2026 was $46.3 million compared with a net loss of $15.1 million for the six months ended June 30, 2025. Adjusted net income (non-GAAP) for the six months ended June 30, 2026 was $6.3 million compared with $2.6 million for the six months ended June 30, 2025.

NET INCOME / (LOSS) PER SHARE

•Net income per share (GAAP) for the second quarter of 2026 was $0.92 compared with net loss per share of $0.32 for the second quarter of 2025. The release of our valuation allowance during the second quarter of 2026 had an $0.87 impact on our net income per share.

•Net income per share (GAAP) for the six months ended June 30, 2026 was $0.95 compared with net loss per share of $0.31 for the six months ended June 30, 2025. The release of our valuation allowance during the six months ended June 30, 2026 had an $0.87 impact on our income per share.

ADJUSTED EBITDA

•Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2026 was $7.4 million, or 26% of revenue, compared with $5.6 million, or 24% of revenue, for the second quarter of 2025.

•Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2026 was $13.5 million, or 24% of revenue, compared with $11.0 million, or 24% of revenue, for the six months ended June 30, 2025.

CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

•Cash, cash equivalents, and marketable securities as of June 30, 2026 were $113.1 million.

(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)

Conference Call & Webcast

Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call.

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development,


			Page 3

manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” “may,” “estimate,” “guidance,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.

While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.


			Page 4

Media & Investor Relations

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

John Graziano

Investor Relations

jgraziano@biolifesolutions.com

Investors

Alliance Advisors IR

Vivian Cervantes

(973) 873-7724

vcervantes@allianceadvisors.com


			Page 5

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share and share data)	2026		2025		2026		2025

Revenue	$	28,466	$	23,438	$	55,966	$	45,492
Cost of revenue	10,179		8,203		20,182		15,457
Gross profit	18,287		15,235		35,784		30,035
Operating expenses:
General and administrative	10,694		11,232		22,901		22,582
Sales and marketing	2,782		2,577		5,308		5,020
Research and development	2,958		1,965		5,608		3,404
IPR&D expense	—		15,521		—		15,521
Intangible asset amortization	157		66		242		132
Total operating expenses	16,591		31,361		34,059		46,659
Operating income (loss)	1,696		(16,126)		1,725		(16,624)

Other income:
Interest income, net	994		684		2,035		1,365
Other income	63		247		242		349

Total other income, net	1,057		931		2,277		1,714

Income (loss) before income tax (benefit) expense	2,753		(15,195)		4,002		(14,910)
Income tax (benefit) expense	(42,351)		126		(42,288)		140
Net income (loss) from continuing operations	$	45,104	$	(15,321)	$	46,290	$	(15,050)

Discontinued operations:
Loss from discontinued operations before income tax expense	—		(517)		—		(1,236)
Income tax benefit	—		—		—		—
Loss from discontinued operations	$	—	$	(517)	$	—	$	(1,236)

Net income (loss)	$	45,104	$	(15,838)	$	46,290	$	(16,286)

Earnings (loss) per share - Basic:
Continuing operations	$	0.92	$	(0.32)	$	0.95	$	(0.31)
Discontinued operations	$	—	$	(0.01)	$	—	$	(0.03)
Net income (loss)	$	0.92	$	(0.33)	$	0.95	$	(0.34)
Earnings (loss) per share - Diluted:
Continuing operations	$	0.91	$	(0.32)	$	0.94	$	(0.31)
Discontinued operations	$	—	$	(0.01)	$	—	$	(0.03)
Net income (loss)	$	0.91	$	(0.33)	$	0.94	$	(0.34)
Weighted average shares used to compute net loss per share attributable to common shareholders:
Basic	48,866,822		47,798,146		48,663,807		47,468,266
Diluted	49,294,679		47,798,146		49,259,528		47,468,266


			Page 6

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)